Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10- 90Y-IMP-288 alone and combined with gemcitabine

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 2008-2016

  Karacay, Habibe ^a   Sharkey, Robert M ^a   Gold, David V ^a   Ragland, Dan R ^b   McBride, William J ^c   Rossi, Edmund A ^d   Chang, Chien Hsing ^c,d   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b Institute of Infectious Diseases   (United States)

^c IMMUNOMEDICS INC   (United States)

^d IBC Pharmaceuticals Inc   (United States)

Author keywords

90Y; Bispecific antibody; Gemcitabine; Pancreatic cancer; Pretargeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO TYROSYL DEXTRO LYSYL(HISTAMINE SUCCINYL GLYCINE) DEXTRO GLUTAMYL DEXTRO LYSYL(HISTAMINE SUCCINYL GLYCINE)AMIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO TYROSYL DEXTRO LYSYL(HISTAMINE SUCCINYL GLYCINE) DEXTRO GLUTAMYL DEXTRO LYSYL(HISTAMINE SUCCINYL GLYCINE)AMIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DI HISTAMINE SUCCINYL GLYCINE Y 90; ANTINEOPLASTIC AGENT; GEMCITABINE; HUMANIZED PAM4 IGG; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TRI FRAGMENT BISPECIFIC MONOCLONAL ANTIBODY TF10; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DOTA TYROSYL LYSYL(HISTAMINYL SUCCINYL GLYCYL) GLUTAMYL LYSYL(HISTAMINYL SUCCINYL GLYCYL)AMIDE; DOTA-TYROSYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)-GLUTAMYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)AMIDE; DRUG DERIVATIVE; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAXIMUM PERMISSIBLE DOSE; MOUSE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG SCREENING; PANCREAS TUMOR; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MICE; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 73349125112     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.067686     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Saif MW. New developments in the treatment of pancreatic cancer: highlights from the "44th ASCO Annual Meeting." Chicago, IL, USA. May 30-June 3, 2008. JOP. 2008;9:391-397.
3. Von Hoff DD, Borad M, Ramanathan RK, et al. Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer [abstract]. Proc Am Assoc Cancer Res. 2008;49:996.
4. Drengler RL, Smith LS, Wood TE, et al. Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer [abstract]. J Clin Oncol. 2008;26(May 20 suppl):656.
5. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994;57:204-210.
6. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24:252-258.
7. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007;13:7380-7387.
8. 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001;7:3186-3192.
9. 90Y-PAM4 combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003;9:3929S-3937S.
10. 90Y-hPAM4 (humanized anti-MUC1 monoclonal antibody) in patients with unresectable and metastatic pancreatic cancer [abstract]. J Nucl Med. 2007;48(suppl 2):393P.
11. Pennington K, Guarino MJ, Serafini AN, et al. Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer [abstract]. J Clin Oncol. 2009;27(May 20 suppl):4620.
12. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 2008;68: 4819-4826.
13. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63: 354-363.
14. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11:7109s-7121s.
15. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11:7879-7885.
16. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68: 5282-5290.
17. 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688.
18. 131I-labeled monoclonal antibody PAM4. Int J Cancer. 1997;71:660-667.
19. Crane CH, Wolff RA, Abbruzzese JL, et al. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol. 2001;28:25-33.
20. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999;59:107-114.
21. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003;9:3712-3721.
22. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 1999;44: 1125-1135.
23. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990; 82:763-771.
24. Liu A, Williams LE, Demidecki AJ, Raubitschek AA, Wong JY. Modeling of tumor uptake to determine the time-dose-fractionation effect in radioimmunotherapy. J Nucl Med. 1994;35:1561-1564.
25. 131I-labeled monoclonal antibody CC49. Cancer Res. 1995;55:5881s-5887s.
26. 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res. 2001;7: 175-184.
27. 177Lulabeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s-7200s.
28. 90Yttrium-DOT-Alabeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004;109:618-626.
29. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2005.
30. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer. 2002;95:941-945.
31. 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice. Br J Cancer. 2008;99:632-638.
32. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1):99S-106S.